Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses
Claire Gorby, Junel Sotolongo Bellón, Stephan Wilmes, Walid Warda, Elizabeth Pöhler, Paul K. Fyfe, Adeline Cozzani, Christophe Ferrand, Mark R. Walter, Suman Mitra, Jacob Piehler, Ignacio Moraga
Abstract
T cells. Moreover, CAR-modified T cells expanded with the engineered IL-10 variant displayed superior cytolytic activity than those expanded with wild-type IL-10. Our study provides insights into how IL-10 receptor complex stability fine-tunes IL-10 biology and opens new opportunities to revitalize failed IL-10 therapies.
Topics & Concepts
Ligand (biochemistry)MedicinePharmacologyBiologyChemistryComputational biologyReceptorGeneticsMonoclonal and Polyclonal Antibodies ResearchImmune Cell Function and InteractionImmunotherapy and Immune Responses